by | Sep 17, 2026 | Uncategorized
Enhertu delayed HER2-mutant lung cancer progression by a median of six months versus Keytruda plus chemo in a Phase 3 trial. Survival is unresolved.
by | Sep 17, 2026 | Uncategorized
Ivonescimab beat Keytruda on survival in a China-only lung cancer trial, but the drug is not approved in the U.S. Here is what patients should know.
by | Sep 17, 2026 | Uncategorized
Two-year ORIGIN 3 data show Trutakna held kidney function nearly steady in IgA nephropathy. What it means for patients, coverage, and approval.
by | Sep 17, 2026 | Uncategorized
Senators questioned Surgeon General nominee Nicole Saphier as COVID-19 rises and measles hits record levels. What the vacancy means for families.
by | Sep 17, 2026 | Uncategorized
Medicare’s ACCESS model adds heart failure, COPD, addiction, and tobacco tracks in spring 2027. Who qualifies, what it may cost, and what to check.
Recent Comments